HCM
TXMD icon

Highbridge Capital Management’s TherapeuticsMD TXMD Stock Holding History

Highbridge Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4,000
Closed -$1.05M – 1783
2017
Q2 		$1.05M Buy
4,000
+1,673
+72% +$419K 0.02% 557
2017
Q1 		$838K Buy
2,327
+1,187
+104% +$367K 0.01% 680
2016
Q4 		$329K Buy
+1,140
New +$353K 0.01% 934
2016
Q1 		– Sell
-10,183
Closed -$5.28M – 1826
2015
Q4 		$5.28M Buy
+10,183
New +$3.76M 0.08% 284
2014
Q4 		– Sell
-561
Closed -$130K – 1437
2014
Q3 		$130K Buy
+561
New +$141K ﹤0.01% 1138

Other funds holding TXMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Highbridge Capital Management's TXMD Position: Q3 2017 in Review

Highbridge Capital Management sold out of TherapeuticsMD (TXMD) in Q3 2017, closing a stake of 4,000 shares — an estimated $1.05M sold.

Highbridge Capital Management first reported a position in TXMD in Q3 2014 and held it in 5 quarters. The position peaked at $5.28M in Q4 2015. 134 funds tracked by Wall St. Rank hold TXMD as of Q3 2017.

  • Highbridge Capital Management reported no remaining TherapeuticsMD position as of Q3 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 4,000 TherapeuticsMD shares in Q3 2017, an estimated $1.05M.
  • Highbridge Capital Management first reported a position in TherapeuticsMD in Q3 2014 and held it in 5 quarters.
  • Highbridge Capital Management's TherapeuticsMD position peaked at $5.28M in Q4 2015.
  • 134 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2017.

Based on Highbridge Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.